| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
L-Leucic acid does not have a specific protein target but is a metabolite of leucine involved in amino acid metabolism. It is used as a synthetic reagent for cryptophycin-based macrocyclic dipeptides, which function as tubulin inhibitors. As a leucine metabolite, it may play a role in muscle protein synthesis and metabolic regulation. The compound's biological activity is primarily related to its role as an endogenous metabolite and its use in peptide synthesis.
|
|---|---|
| ln Vitro |
In vitro, L-leucic acid is used as a synthetic reagent for the preparation of cryptophycin-based macrocyclic dipeptides, which function as tubulin inhibitors. As a leucine metabolite, it is involved in amino acid metabolism. Detailed in vitro biological activity data for the compound itself are not extensively reported in the available literature, as it is primarily used as a synthetic intermediate and reference standard.
|
| ln Vivo |
Detailed in vivo activity data for L-leucic acid are not extensively reported in the available literature. As a leucine metabolite, it may play a role in muscle protein synthesis and metabolic regulation. It is used as a muscle builder, suggesting potential applications in sports nutrition and metabolic research. However, specific in vivo efficacy data from animal studies are not provided in the available sources.
|
| Enzyme Assay |
Non-cell-based assays for L-leucic acid are not typical, as it is primarily used as a synthetic intermediate and reference standard. However, its purity and optical purity can be assessed using analytical techniques such as HPLC, GC, and polarimetry. As a tubulin inhibitor precursor, its activity would be assessed through tubulin polymerization assays after conversion to the active dipeptide.
|
| Cell Assay |
Cellular assays for L-leucic acid are not typical, as it is primarily used as a synthetic intermediate. However, its effects on muscle cells could be studied to assess its role as a leucine metabolite. Cells are treated with the compound, and markers of protein synthesis, such as mTOR pathway activation, could be measured. These studies would be relevant for understanding its metabolic role.
|
| Animal Protocol |
In vivo animal models for L-leucic acid would be required to assess its therapeutic potential. Based on its role as a leucine metabolite and muscle builder, relevant models could include studies of muscle protein synthesis in rodents. The compound would be administered via appropriate routes, and muscle mass, protein synthesis rates, and metabolic parameters would be measured.
|
| ADME/Pharmacokinetics |
L-Leucic acid has a molecular weight of 132.16 g/mol and a molecular formula of C₆H₁₂O₃. CAS number is 13748-90-8. Melting point is 77.0 to 82.0°C. Optical purity is ≥98.0% ee. Purity is ≥99.0%. Appearance is a white to almost white powder or crystal. Storage conditions: room temperature (below 15°C in a dry, dark place).
|
| Toxicity/Toxicokinetics |
L-Leucic acid is generally considered safe for research use. As an amino acid metabolite, it has a low toxicity profile. Detailed toxicological data are not extensively reported. The compound is supplied for research use only and is not for human consumption. Standard laboratory safety precautions should be followed when handling the compound.
|
| Additional Infomation |
(S)-2-hydroxy-4-methylvaleric acid is the (S)-enantiomer of 2-hydroxy-4-methylvaleric acid. It originates from the metabolism of branched-chain amino acids and belongs to the 2-hydroxycarboxylic acid class of amino acid metabolites. It is a 2-hydroxy-4-methylvaleric acid and also a (2S)-2-hydroxy monocarboxylic acid. It is an enantiomer of (R)-2-hydroxy-4-methylvaleric acid. L-leucine has been reported in Brassica napus and Aeromonas veronii, and relevant data are available.
L-Leucic acid is also known as (S)-2-hydroxy-4-methylvaleric acid and (S)-α-hydroxyisocaproic acid. It is a metabolite of the branched-chain amino acid leucine. The compound is a synthetic reagent for cryptophycin-based macrocyclic dipeptides used as tubulin inhibitors. It is an amino acid metabolite used as a muscle builder. L-Leucic acid is used in research applications studying amino acid metabolism and peptide synthesis. It is for research use only. |
| Molecular Formula |
C6H12O3
|
|---|---|
| Molecular Weight |
132.15
|
| Exact Mass |
132.078
|
| CAS # |
13748-90-8
|
| Related CAS # |
(R)-Leucic acid;20312-37-2
|
| PubChem CID |
83697
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
251.3±13.0 °C at 760 mmHg
|
| Melting Point |
78-80ºC(lit.)
|
| Flash Point |
120.1±16.3 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.458
|
| LogP |
0.71
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
9
|
| Complexity |
98.5
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(C)C[C@@H](C(=O)O)O
|
| InChi Key |
LVRFTAZAXQPQHI-YFKPBYRVSA-N
|
| InChi Code |
InChI=1S/C6H12O3/c1-4(2)3-5(7)6(8)9/h4-5,7H,3H2,1-2H3,(H,8,9)/t5-/m0/s1
|
| Chemical Name |
(2S)-2-hydroxy-4-methylpentanoic acid
|
| Synonyms |
EINECS 237-329-6; Leucic acid, L-
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~756.66 mM)
DMSO : ~50 mg/mL (~378.33 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (18.92 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (18.92 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (18.92 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (756.66 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.5672 mL | 37.8358 mL | 75.6716 mL | |
| 5 mM | 1.5134 mL | 7.5672 mL | 15.1343 mL | |
| 10 mM | 0.7567 mL | 3.7836 mL | 7.5672 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
